Clinical trial: Colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 8, 2010, Pages 984-989

  Gustavsson, A ^a   Jarnerot G ^a   Hertervig, E ^b   Friis Liby, I ^c   Blomquist, L ^d   Karlen P ^e   Granno C ^f   Vilien, M ^g   Strom M ^h   Verbaan, H ^b   Hellstrom P M ^d   Magnuson, A ^a   Halfvarson, J ^a   Tysk, C ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e STOCKHOLM SÖDER HOSPITAL   (Sweden)

^f RYHOV COUNTY HOSPITAL   (Sweden)

^g HILLERØD HOSPITAL   (Denmark)

^h LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETAMETHASONE; INFLIXIMAB; MESALAZINE; PLACEBO;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON RESECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENDOSCOPY; FOLLOW UP; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT INDICATION; ULCERATIVE COLITIS;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS, ULCERATIVE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; LOGISTIC MODELS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957226063     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04435.x     Document Type: Article

References (33)

1. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut 1963 4: 299 315.
2. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007 5: 103 110. (Pubitemid 46096828)
3. Järnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985 89: 1005 1013. (Pubitemid 16231562)
4. Gustavsson A, Halfvarson J, Magnuson A, Sandberg-Gertzen H, Tysk C, Järnerot G. Long-term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era. Am J Gastroenterol 2007 102: 2513 2519. (Pubitemid 47631769)
5. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994 330: 1841 1845. (Pubitemid 24188135)
6. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003 125: 1025 1031. (Pubitemid 37193449)
7. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005 17: 79 84. (Pubitemid 40128931)
8. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006 4: 760 765. (Pubitemid 43833506)
9. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003 52: 998 1002. (Pubitemid 36765292)
10. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001 7: 83 8.
11. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005 128: 1805 1811. (Pubitemid 40824691)
12. Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007 25: 19 37. (Pubitemid 44902861)
13. Lindgren SC, Flood LM, Kilander AF, Löfberg R, Persson TB, Sjödahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998 10: 831 835.
14. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992 87: 971 976.
15. Hjortswang H, Jarnerot G, Curman B, et al. The Short Health Scale: a valid measure of subjective health in ulcerative colitis. Scand J Gastroenterol 2006 41: 1196 1203. (Pubitemid 44451683)
16. Sullivan M, Karlsson J, Ware JE Jr. The Swedish SF-36 Health Survey - I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med 1995 41: 1349 1358.
17. Taft C, Karlsson J, Sullivan M. Performance of the Swedish SF-36 version 2.0. Qual Life Res 2004 13: 251 256. (Pubitemid 38315238)
18. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987 317: 1625 1629.
19. Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther 2007 25: 1055 1060. (Pubitemid 46587696)
20. Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007 26: 747 756. (Pubitemid 47246204)
21. Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007 26: 411 419. (Pubitemid 47063146)
22. Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol 2006 40: 476 481. (Pubitemid 44318131)
23. Yamamoto-Furusho JK, Uzcanga LF. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids. Dig Surg 2008 25: 383 386.
24. Bressler B, Law JK, Al Nahdi Sheraisher N, et al. The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis. Can J Gastroenterol 2008 22: 937 940.
25. Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis 2008 40: 821 826.
26. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353: 2462 2476. (Pubitemid 41770166)
27. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009 137: 1250 1260.
28. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2009 16: 338 346.
29. Froslie KF, Jahnsen J, Moum BA, Vatn MH, Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007 133: 412 422. (Pubitemid 47187355)
30. Actis GC, Fadda M, David E, Sapino A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol 2007 7: 13. (Pubitemid 46604973)
31. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999 94: 1587 1592. (Pubitemid 29260450)
32. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006 55: 47 53. (Pubitemid 41820634)
33. Travis SPL, Stange EF, Lémann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. Journal of Crohn's and Colitis 2008 2: 24 62. (Pubitemid 351179488)